The in vitro effect of antirheumatic drugs on platelet function

The in vitro effect of antirheumatic drugs on platelet function

Several antirheumatic drugs lower the cardiovascular risk among rheumatoid arthritis patients. It is, however, unknown whether inhibition of platelet function contributes to this risk reduction. Only few studies have investigated the potential role of platelets as a target of antirheumatic drugs. In...

Full description

Bibliographic Details
Main Authors:	Camilla Brødsgaard Nielsen, Christian Nielsen, Mads Nybo, Søren Andreas Just, Pernille Just Vinholt
Format:	Article
Language:	English
Published:	Taylor & Francis Group 2020-02-01
Series:	Platelets
Subjects:	cardiovascular disease experimental study pharmacology platelet function rheumatoid arthritis
Online Access:	http://dx.doi.org/10.1080/09537104.2019.1609665

Similar Items

Reduced platelet activation and platelet aggregation in patients with alcoholic liver cirrhosis
by: Pernille Just Vinholt, et al.
Published: (2018-07-01)

In vitro effect of biological and conventional disease-modifying antirheumatic drugs on fibrocyte differentiation in patients with rheumatoid arthritis and healthy controls
by: Helene Broch Tenstad, et al.
Published: (2021-10-01)

Mean Platelet Volume in a Series of 315 Patients with Rheumatoid Arthritis: Relationship with Disease Characteristics, including Subclinical Atherosclerosis and Cardiovascular Comorbidity
by: Marta González-Sierra, et al.
Published: (2023-10-01)

Patients With Rheumatoid Arthritis With an Inadequate Response to Disease‐Modifying Antirheumatic Drugs at a Higher Risk of Acute Coronary Syndrome
by: Chung‐Yuan Hsu, et al.
Published: (2021-04-01)

Value of Platelet Distribution Width and Mean Platelet Volume in Disease Activity Score of Rheumatoid Arthritis
by: Khaled SAA, et al.
Published: (2020-09-01)

Immunogenicity of Sarilumab Monotherapy in Patients with Rheumatoid Arthritis Who Were Inadequate Responders or Intolerant to Disease-Modifying Antirheumatic Drugs
by: Alvin F. Wells, et al.
Published: (2019-05-01)

IMPACT OF ANTIRHEUMATIC THERAPY ON THE LEVEL OF N-TERMINAL PRO-BRAIN NATRIURETIC PEPTIDE IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS
by: I. G. Kirillova, et al.
Published: (2018-07-01)

Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
by: Ronald van Vollenhoven, et al.
Published: (2018-10-01)

The bleeding diathesis in patients with hereditary haemorrhagic telangiectasia is not due to impaired platelet function
by: Anne Lørup Lyster, et al.
Published: (2023-11-01)

Left and right ventricular diastolic dysfunction in patients with early rheumatoid arthritis before prescribing disease-modifying antirheumatic therapy
by: I G Kirillova, et al.
Published: (2015-05-01)

Fibrocyte measurement in peripheral blood correlates with number of cultured mature fibrocytes in vitro and is a potential biomarker for interstitial lung disease in Rheumatoid Arthritis
by: Søren Andreas Just, et al.
Published: (2017-07-01)

CARDIOVASCULAR RISK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS BEFORE DISEASE-MODIFYING ANTIRHEUMATIC THERAPY (PRELIMINARY DATA OF THE REMARCА STUDY)
by: Yu. N. Gorbunova, et al.
Published: (2014-09-01)

Platelet signaling at the nexus of innate immunity and rheumatoid arthritis
by: Steven Z. Jiang, et al.
Published: (2022-11-01)

Platelet indices in patients with chronic inflammatory arthritis: a systematic review and meta-analysis
by: Zhongwei Zhou, et al.
Published: (2020-10-01)

Potential role of platelets for atherosclerotic events in rheumatoid arthritis
by: Rosa Vona, et al.
Published: (2018-12-01)

The Relationship between Platelet Indices and Ultrasound, Clinical, Laboratory Parameters of Disease Activity in Patients with Rheumatoid Arthritis
by: Bożena Targońska-Stępniak, et al.
Published: (2021-11-01)

Pharmacological Aspects of Natural Quercetin in Rheumatoid Arthritis
by: Tang M, et al.
Published: (2022-06-01)

Initiation Patterns of Disease‐Modifying Antirheumatic Drugs That Have Potential to Exacerbate Heart Failure
by: Su Been Lee, et al.
Published: (2023-07-01)

Is it possible to discontinue glucocorticoids in rheumatoid arthritis with the use of synthetic disease-modifying antirheumatic drugs?
by: O. B. Iaremenko, et al.
Published: (2023-07-01)

Treatment adherence to disease-modifying antirheumatic drugs in Chinese patients with rheumatoid arthritis
by: Xia Y, et al.
Published: (2016-05-01)

Anti-arthritic action of cardamonin in rheumatoid arthritis-induced rat model
by: Voon, Fui Ling
Published: (2016)

Factors associated with initial or subsequent choice of biologic disease-modifying antirheumatic drugs for treatment of rheumatoid arthritis
by: Yinzhu Jin, et al.
Published: (2017-07-01)

TIME COURSE OF CHANGES IN BLOOD LIPID PARAMETERS IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS DURING TREAT-TO-TARGET ANTIRHEUMATIC THERAPY: ACCORDING TO 18-MONTH FOLLOW-UP FINDINGS
by: E. V. Udachkina, et al.
Published: (2016-07-01)

Association between Mean Platelet Volume and Bone Mineral Density in Rheumatoid Arthritis
by: Betül Sargın
Published: (2021-05-01)

Mechanisms of storage and release of vasoactive molecules in endothelial cells – Endothelin-1
by: Banecki, KMRM
Published: (2024)

Increase of Circulating Monocyte–Platelet Conjugates in Rheumatoid Arthritis Responders to IL-6 Blockage
by: Anaís Mariscal, et al.
Published: (2022-05-01)

Inhibition of IL-17 signaling in macrophages underlies the anti-arthritic effects of halofuginone hydrobromide: Network pharmacology, molecular docking, and experimental validation
by: Junping Zhu, et al.
Published: (2024-02-01)

Cardiovascular risk of Janus kinase inhibitors compared with biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis without underlying cardiovascular diseases: a nationwide cohort study
by: Yun-Kyoung Song, et al.
Published: (2023-10-01)

Candidate antirheumatic genotherapeutic plasmid constructions have low immunogenicity
by: T. S. Nepomnyashchikh, et al.
Published: (2017-05-01)

HEALTH ECONOMIC ASSESSMENT OF ANTIRHEUMATIC DRUGS IN PATIENTS WITH REUMATHOID ARTHRITIS PROGRESSED AFTER METOTREXATE
by: A. S. Kolbin, et al.
Published: (2016-12-01)

Rac1 regulates platelet microparticles formation and rheumatoid arthritis deterioration
by: Xue Chen
Published: (2020-01-01)

Genetic Polymorphisms Associated with Rheumatoid Arthritis Development and Antirheumatic Therapy Response
by: Dmitry S. Mikhaylenko, et al.
Published: (2020-07-01)

Chronic Heart Failure in Early Rheumatoid Arthritis Patients Prior to Basic Antirheumatic Therapy
by: I. G. Kirillova, et al.
Published: (2020-03-01)

Discovery of Tricyclic Pyranochromenone as Novel Bruton’s Tyrosine Kinase Inhibitors with In Vivo Antirheumatic Activity
by: Hyewon Cho, et al.
Published: (2020-10-01)

N-terminal pro-brain natriuretic peptide levels and diastolic dysfunction in patients with early rheumatoid arthritis before the administration of disease-modifying antirheumatic drugs
by: I G Kirillova, et al.
Published: (2016-05-01)

Sustained Long-Term Retention Rates of Abatacept in Combination with Conventional Synthetic Disease-Modifying Antirheumatic Drugs in Elderly Patients with Rheumatoid Arthritis
by: Shuzo Sato, et al.
Published: (2021-08-01)

Aspirin effectiveness in patients with rheumatoid arthritis and coronary heart disease who receive non-steroidal anti-inflammatory drugs
by: T. V. Kropotina, et al.
Published: (2013-04-01)

Methotrexate improves endothelial function in early rheumatoid arthritis patients after 3 months of treatment
by: Giacomo Cafaro, et al.
Published: (2022-10-01)

Platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in patients with rheumatoid arthritis
by: Peng You-Fan, et al.
Published: (2015-04-01)

Platelets derived citrullinated proteins and microparticles are potential autoantibodies ACPA targets in RA patients
by: Minjie Xu, et al.
Published: (2023-01-01)